“People around the world have mysterious notions about the vagina,” Sharon Hillier told a group of journalists and advocates today. Hillier, one of five co-chairs of HIV R4P, the first global conference devoted to biomedical HIV prevention research, is here to explain her work, which she sums up as making vaginas much more resistant to […](Read more...)
28 October 2014 | Science Speaks
Australian biotech company Starpharma has announced the imminent launch of a condom coated with an antimicrobial chemical known as VivaGel. While it might be marketed as a great leap forward for preventing sexually transmitted infections (STIs), it’s unlikely to offer any more protection than your average condom.
14 October 2014 | The Conversation
IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.
02 October 2014 | IRMA
Give OUT Day shines a spotlight on organizations that empower LGBTQ communities across the country, and the AIDS Foundation of Chicago (AFC) is among these charities.We’re using this campaign to highlight the next generation of HIV prevention: rectal microbicides. Though they’re still in development, these agents can be added to things like lubricants that will prevent the transmission of HIV, revolutionizing the way we protect ourselves and others.
25 September 2014 | IRMA
The U.S. National Institutes of Health devoted $20 million to a group of institutions including Miriam Hospital in Rhode Island to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.
15 September 2014 | Fierce Drug Delivery
A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences.
A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug-delivery vehicle that can protect against the spread of sexually transmitted infections during unprotected heterosexual intercourse, the researchers said.
02 September 2014 | Medical News Today
Scientists use a method of weaving the drug into silk-like fibers that dissolve quickly when inserted into the vagina before sex, delivering a higher dose than is possible with other topical methods currently being tested.
05 August 2014 | Business Journal
MTN’s trial testing dapivirine ring on track to finish next year; IPM’s sister Phase III trial ongoing.
30 June 2014 | Microbicide Trials Network
Tenofovir 1% gel applied rectally yielded rectal tissue concentrations orders of magnitude greater than those achieved with oral tenofovir, according to results of an 18-person study by US researchers. Systemic tenofovir exposure was lower with 1% gel than with oral tenofovir, but vaginal exposure was greater with the rectal gel.
02 June 2014 | NATAP
The International Partnership for Microbicides (IPM) announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
09 May 2014 | International Partnership for Microbicides